

PATENT

CEDAR 43453 (18810-80645)

April 28, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Keith L. Black and Nagendra S. Ningaraj

Serial No.

09/491,500

Filed:

January 26, 2000

For:

METHOD FOR USING POTASSIUM CHANNEL

AGONISTS FOR DELIVERING A MEDICANT TO AN

ABNORMAL BRAIN REGION AND/OR A MALIGNANT

TUMOR

Examiner:

Falk, Anne Marie

Unit:


1632

Confirmation No:

8610

TRANSMITTAL OF AND RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Mail Stop Sequence Commissioner for Patents P. O. Box 1450 Arlington, VA 22213-1450



MAY 0 8 2003

Dear Sir or Madam:

TECH CENTER 1600/2900

This is in Response to the Office Communication mailed April 10, 2003, for the above-captioned patent application. This response is submitted on or before May 10, 2003. Applicant has corrected the sequence listing to identify the organism as *Homo sapiens*.

In compliance with the requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures, applicant respectfully submits:

- copy of Notice to Comply with Requirements for Patent
 Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence
 Disclosures;
 - 2) a paper copy of corrected sequence listing;
 - 3) computer readable copy of sequence listing; and
- 4) statement verifying identical paper and computer readable copy and with respect to there being no new matter.

Respectfully submitted,

Nisan A. Steinberg, Ph.D. Registration No. 40,345

SIDLEY AUSTIN BROWN & WOOD LLP 555 West Fifth Street Los Angeles, California 90013-1010

Ofc: 213/ 896-6665 Fax: 213/896-6600

Application	: 09/491,500	
-------------	--------------	--

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from EVED

7. Other:

TECH CENTER 1600/2900

Applicant Must Provide:

A substitute computer readable form (CRF) copy of the "Sequence Listing".

A substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(q) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support

To Purchase Patentin Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information

Center (STIC) detected errors when processing the following computer readable
form:

RECEIVED

Application Serial Number: 09/491,500 MAY 0 8 2003 Source: 1609 Date Processed by STIC: 2/19/2003 TECH CENTER 1600/2900

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,

2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216. PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax) PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE <u>CHECKER</u> <u>VERSION 3.1 PROGRAM</u>, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>, EFS Submission User Manual-ePAVE)
- 2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
- 3. Hand Carry directly to:
 U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
 - U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
- Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002



SUGGESTED CORRECTION

RECEIVED

FEB 2 5 2003

TECH CENTER 1600/2900

Raw Sequence Listing Error Summary

ERROR DETECTED

serial number: <u>09/4</u>91, 500

TTN: NEW RULES CASES	: Please disregard english "Alpha" headers, which were inserted by PTO	SOFTWARE
1Wrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."	RECEIVED
2Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.	MAY 0 a assa
3 Misaligned Amino Numbering	The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.	MAY 0 8 2003
4Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please The ensure your subsequent submission is saved in ASCII text.	ECH CENTER 1600/2900
5Variable Length	Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.	
6Patentin 2.0 "bug"	A "bug" in Patentin version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) Normally, Patentin would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.	غريفهنيم
7Skipped Sequences (OLD RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped	
	Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to Include the skipped sequences.	
8 Skipped Sequences (NEW RULES)	Sequence(s) missing. If Intentional, please insert the following lines for each skipped sequence <210> sequence id number <400> sequence id number 000	
9Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa; and which residue n or Xaa represents.	
Invalid <213> Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown of the Artificial Sequence	nae.
11Use of <220>	Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)	
PatentIn 2.0 "bug"	Please do not use "Copy to Disk" function of Patentin version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.	
13Misuse of n	n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.	

AMC/MH - Biotechnology Systems Branch - 08/21/2001





1600

RAW SEQUENCE LISTING

DATE: 02/19/2003

PATENT APPLICATION: US/09/491,500

TIME: 13:49:00

Input Set : A:\Seqlist.txt

Output Set: N:\CRF4\02192003\I491500.raw

RECEIVED

4 <110> APPLICANT: Keith L. Black
Nagendra Ningaraj
8 <120> TITLE OF INVENTION: METHOD FOR USING POTASSIUM CHANNEL
9 AGONISTS FOR DELIVERING A MEDICANT TO AN ABNORMAL BRAIN
10 REGION AND/OR A MALIGNANT TUMOR
13 <130> FILE REFERENCE: CEDAR-043453 (80645)
15 <140> CURRENT APPLICATION NUMBER: 09/491,500
16 <141> CURRENT FILING DATE: 2000-01-26
18 <160> NUMBER OF SEQ ID NOS: 1
20 <170> SOFTWARE: FastSEQ for Windows Version 4.0
22 <210> SEQ ID NO: 1
23 <211> LENGTH: 9
24 <212> TYPE: PRT
25 <213> ORGANISM: Amino acid
27 <400> SEQUENCE: 1
28 Arg Pro Pro Gly Phe Ser Pro Phe Arg
29 1
5

MAY 0 8 2003

MAY 0 8 2003

TECH CENTER 1600/2900

TO CONTECTED 1600/2900

TO CONTECTED 1600/2900

TO SEQUENCE: 1

DOOS NOT Comply
CONTECTED DISKette Needed

CONTECTED DISKette Needed

VERIFICATION SUMMARY

DATE: 02/19/2003

PATENT APPLICATION: US/09/491,500

TIME: 13:49:01

Input Set : A:\Seqlist.txt

Output Set: N:\CRF4\02192003\I491500.raw